| Course | NR 506 Health Care Policy |
|---|---|
| Week | 6 |
| Paper type | Interest group analysis |
| Length | About 1,330 words, 3 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NR 506 Week 6
Who Was on the Record About a Private-Plan Insulin Cap: Seven Letters Placed in the Congressional Record on March 31, 2022, Large Employers Blaming Manufacturers and Pharmacy Benefit Managers, and the Insulin Users No Organization Spoke For
Student Name
College of Nursing, Chamberlain University
NR 506: Health Care Policy
Instructor Name
Month Day, Year
Who Was on the Record About a Private-Plan Insulin Cap: Seven Letters Placed in the Congressional Record on March 31, 2022, Large Employers Blaming Manufacturers and Pharmacy Benefit Managers, and the Insulin Users No Organization Spoke For
A Question With Sides
The question for this analysis is the one my Week 2 brief asked Congress to answer: should federal law cap what people with private employer coverage, including self-funded plans, pay out of pocket for insulin? It has sides because the cost of a cap does not disappear. It moves from patients to plans, and from plans to employers and premiums, and the groups who would carry that cost have organized voices.
Rather than describe interests from impressions, this analysis is built from one set of documents: the letters placed in the Congressional Record on March 31, 2022, the day the House passed the Affordable Insulin Now Act (Congressional Record, 2022). During debate, Representative Adrian Smith of Nebraska, managing time for the opposition, entered letters "from numerous groups" into the record. Every organization profiled below is one that filed something on that record.
Named Bodies, the Same Four Fields Each
Each organization is described by who it says it represents, what position it took, what it proposed instead and how it describes its own base. Funding is recorded only as the organization described itself in the letter; where a letter said nothing about money, the table says so rather than guessing.
Table 1
Organizations With Letters in the Congressional Record, March 31, 2022
| Organization and signer | Whom it says it represents | Position and main argument | What it proposed instead |
|---|---|---|---|
| The ERISA Industry Committee (ERIC), James P. Gelfand, March 29 | The largest U.S. employers as sponsors of employee benefit plans | Vote no; the bill sets government prices, shifts costs to patients and plans and will not lower drug costs | More competition among insulin makers, fixing how insulin is regulated and patented, and reform of rebates and service fees |
| Partnership for Employer-Sponsored Coverage (P4ESC), March 30 | Employer organizations and trade associations for businesses of all sizes | Strong concerns; the bill shifts costs back to employers and employees | Action against profit-taking by manufacturers and pharmacy benefit managers |
| NFIB, Kevin Kuhlman, March 30 | Small businesses | Concern; a laudable goal, but premiums will rise for small employers | Address the underlying cost drivers, including pharmacy benefit manager practices |
| AMAC Action, Bob Carlstrom, March 30 | About 2.3 million members aged 55 and older | Concern; an election-year measure paid for by delaying the rebate rule | Build on the Part D Senior Savings Model |
| Council for Citizens Against Government Waste (CCAGW), Tom Schatz, March 30 | More than one million members and supporters | Oppose; price controls that threaten research | No specific alternative beyond avoiding price controls |
| FreedomWorks, March 30 | Its activist community | Key vote no; price controls | Letter blames government and pharmacy benefit managers |
| National Taxpayers Union (NTU), undated in the record | Taxpayers | Concerns; about $11 billion in federal cost and a rebate-rule delay it called a budget gimmick | A Medicare Part D out-of-pocket cap with benefit redesign, the Medicare insulin model and spreading Part D costs across the year |
Note. All descriptions are taken from the letters as printed (Congressional Record, 2022). None of the letters stated its funding sources.
Reading the Employer Letters Closely
The three employer letters matter most for my question, because employers, especially large self-funded ones, are the people a private-plan cap would actually bind. They share three claims. First, a cap shifts costs rather than reducing them: in the words of P4ESC, the bill would "simply shift costs back to employers and employees, including those who are insulin dependent." Second, premiums would rise; ERIC and P4ESC both cited a Congressional Budget Office finding that the bill would add about $11 billion to the federal deficit and raise premiums. Third, the real problem lies upstream, with manufacturers and pharmacy benefit managers.
ERIC's letter adds a claim that deserves attention because it can be tested: that a cap creates "a perverse incentive" in which manufacturers can raise prices knowing patients will pay a fixed amount. That argument predicts that list prices would rise after caps. The opposite happened after 2023, when major manufacturers cut list prices, though, as my Week 4 analysis noted, for reasons that probably had more to do with Medicaid rebate law than with caps.
Who Had No Organization
The most striking feature of the record is who is absent. No letter from a diabetes patient organization, a nursing organization or a consumer group appears among those placed in the record that day. The members who spoke for the bill, such as Representative Danny K. Davis of Illinois, who described living with type 2 diabetes for 30 years, spoke from their own experience and their districts rather than from filed letters. That does not mean patient groups took no position; it means none of their positions were entered into this record.
The group with the most at stake, insulin users in self-funded employer plans, has no organization of its own at all. ERIC speaks for the employers who sponsor their coverage, and says its members pay about 75% of health care costs for 181 million beneficiaries. The employees themselves, whose deductibles decide what they pay at the pharmacy, are represented in this debate by the organizations of the people who design their plans. That is not a criticism of ERIC; it is a structural fact about self-funded coverage that any advocacy strategy has to account for.
Alignments That Surprise
Three alignments cut across the usual lines. The first is that large employers and the bill's supporters agree about the villains. ERIC, P4ESC and NFIB all named pharmacy benefit managers and manufacturer practices as causes of high insulin costs, which is the same diagnosis many of the bill's supporters gave on the floor. They disagreed about the remedy, not the cause.
The second is AMAC's defense of the rebate rule. AMAC objected that the bill was paid for by delaying the 2020 rule that would have moved manufacturer rebates to the point of sale, which it described as a Trump-era rule that would lower beneficiaries' out-of-pocket costs. That puts a conservative seniors' group in the position of defending a federal regulation against a Democratic bill that used it as a budget offset, which is an unusual line-up and a useful reminder that positions follow stakes more than labels.
The third is the taxpayer group. The National Taxpayers Union opposed the bill, yet its letter listed an out-of-pocket cap in Medicare Part D among the proposals it supported, as part of a Part D redesign. Five months later, that is roughly what the Inflation Reduction Act enacted. An opponent of the bill on the record was, on the Medicare half of it, closer to the eventual law than to the other opponents.
Reading the Text Back
Read back against the bill's text, the employer letters are strongest on one point and weakest on another. They are right that the private-plan cap would move cost onto plans; the bill does nothing about the price plans pay. They are weaker on the claim that the bill "will not lower drug costs": it was never designed to lower drug prices, only patients' share. For my own advocacy, the analysis suggests two changes. A nursing association should pair any cap proposal with the supply-chain reforms employers themselves named, which would turn the strongest opponents into possible allies. And it should put insulin users' own voices on the record, because on the one day the House decided this question, the only organized voices filed were on the other side.
References
Congressional Record. (2022, March 31). Affordable Insulin Now Act (House of Representatives, Vol. 168, No. 57, pp. H4033-H4055). U.S. Government Publishing Office.
What the NR 506 Week 6 assignment asks for
The Week 6 analysis has you examine the stakeholders and interest groups in a health policy debate. Students are usually asked for the issue, the groups involved, their positions and interests, their resources and influence, alignments or conflicts and APA. Build the analysis from a set of documents, such as letters on the record, rather than assumptions. Describe each group with the same fields. Read the most important group's arguments closely and test any claim that can be checked. Note who is absent from the record. Look for alignments that cut across the usual lines. Read the arguments back against the policy's actual text.
Inside the NR 506 Week 6 example
The question section restates whether federal law should cap insulin costs in private and self-funded plans. The source section explains why the analysis uses the Congressional Record letters. Table 1 lists seven organizations, including ERIC, P4ESC, NFIB, AMAC and the National Taxpayers Union, with the four fields taken from their letters and a note that none stated funding. The employer section reads three letters and tests ERIC's claim that a cap lets manufacturers raise prices against the 2023 cuts. The absence section notes no patient, nursing or consumer letter. The alignments section shows employers blaming manufacturers, AMAC defending the rebate rule and the taxpayer group listing a Part D cap among its own ideas. The last section reads the letters against the text.
NR 506 Week 6 rubric: what full points look like
Interest group rubrics in NR 506 typically weigh identification of stakeholders, accurate positions, analysis of interests and influence, attention to absent voices, use of primary documents and APA. This analysis stands on primary documents: every description comes from the letters as printed. Positions are credited for the same four fields per group. Analysis scores through the tested claim and the three alignments. Absent voices earn points because the group with most at stake has no organization of its own. Reading the letters back against the bill shows critical judgment. The Congressional Record is the single source, used with care. A single source read closely beats many sources read loosely.
Common NR 506 Week 6 mistakes, and how to avoid them
Analyses lose most heavily when interests are asserted from stereotype, such as insurers wanting profit, with nothing cited. Another loss is describing groups with different fields, so they cannot be compared. Students also accept every claim at face value, ignore who is missing or claim a group bought an outcome without evidence. Primary documents such as testimony and letters are free through government sites. Your own professional organization can be included if it took a position. Keep claims about influence to what the record shows. Name the debate you are studying, and an NR 506 interest group analysis can be built from documents on the record. Quote each group's own words.
Get a NR 506 Week 6 example written to your instructions
Send the Week 6 instructions and the policy question, and an analysis built from public filings and published positions comes back inside 24-48h, the first one free. Where your section posts a matrix with fixed columns, every profile is entered into those columns so that nothing needs reformatting once it reaches you.
More NR 506 papers and MSN samples
- NR 506 Week 1: Health Policy at Work Discussion Post
- NR 506 Week 2: Insulin Cost Policy Issue Brief
- NR 506 Week 3: Insulin Bill Legislative Process Paper
- NR 506 Week 4: Medicare Insulin Cap Policy Analysis
- NR 506 Week 5: Federal Rulemaking Process Write-Up
- NR 506 Week 7: Policy Evaluation Write-up
- NR 506 Week 8: Policy Synthesis Paper
- NR 506NP Week 6: Professional Organization Analysis
- NR 505 Week 6: Measurement and Sampling Write-Up
- NR 508 Week 6: Therapeutic Failure Write-up
- NR 504 Week 6: Delegation Accountability Case Paper
NR 506 Week 6 questions, answered
Where is this information without paying for a database?
More is public than students expect. Lobbying registrations, campaign finance filings, tax returns for nonprofit organizations and the comment record on a proposed rule are all free to search, and professional bodies publish position statements themselves. Annual reports name funders. What none of these gives you is motive, so the write-up stays with what was filed, by whom, and when.
Should my own professional organization be on the list?
Yes, and treating it with the same skepticism as everybody else is usually what lifts the grade. A nursing body arguing for a change that expands its members' work has a material stake, and saying so does not undermine the argument, it only makes the analysis consistent. An analysis where every party has an interest except the writer's own reads as partial.
Can I say a group bought the outcome?
Not as a finding. You can report a contribution, a filing and a vote, with dates, and let the sequence sit there without a verb joining them. Rubrics in this course tend to reward exactly that restraint, because the causal claim is unprovable and the documented order of events is not. Frame it as what the record is consistent with.
Where can I find a free NR 506 Week 6 sample paper?
Read the full Week 6 study of seven Congressional Record letters on a private insulin cap: with the table, the employer letters, the absent voices, three alignments and the source.
Who is missing from the record in the NR 506 Week 6 analysis?
Patient, nursing and consumer organizations, and above all insulin users in self-funded employer plans, who have no organization of their own speaking for them.